Key Takeaways A new ICD-10 diagnosis code, E11.A, now formally recognizes type 2 diabetes in remissionRemission requires an ...

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

A diabetes diet is a healthy eating plan that helps control your blood sugar. Here are the best foods to eat, no matter what type of diabetes you have.

Eli Lilly's experimental oral weight-loss drug, orforglipron, demonstrated superior blood sugar control in diabetic patients ...

Eli Lilly's experimental weight-loss pill, orforglipron, demonstrated superior blood sugar control in late-stage trials involving diabetic patients.

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

Misdiagnosis of type 1 diabetes in adults and of monogenic diabetes at all ages often occurs, with adverse consequences.